Data as of Sep 19
| -0.74 / -5.47%|
The 5 analysts offering 12-month price forecasts for Stemline Therapeutics Inc have a median target of 50.00, with a high estimate of 75.00 and a low estimate of 44.00. The median estimate represents a +290.93% increase from the last price of 12.79.
The current consensus among 5 polled investment analysts is to Buy stock in Stemline Therapeutics Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.